Chinese Pharmacopoeia 2020 Edition: Official English Translation Issued

(Update Notice: This post covers the Chinese Pharmacopoeia 2020 edition. Refer to Chinese Pharmacopoeia 2025: Key Updates and What You Need to Know for the latest standards and updates).

The English edition of the Chinese Pharmacopoeia (ChP) 2020 was officially published by the Chinese Pharmacopoeia Commission (CPC) on 14 March 2023. The Chinese edition was released on July 2, 2020, and became effective on December 30, 2020.

The document provides a detailed overview of the China quality standards and specifications for drugs and pharmaceutical products, making it an essential reference for both manufacturers and users of drugs around the world.

For support in interpreting the topics of the Chinese Pharmacopoeia, get in contact with Cisema today. Alternatively, explore our pharmaceutical services for international companies entering and operating in China.

Key Highlights of the Chinese Pharmacopoeia 2020

The Chinese Pharmacopoeia is updated every five years to reflect scientific advances, regulatory developments, and evolving quality expectations.

Compared with the 2015 edition, the 2020 edition includes 5,911 monographs, consisting of:

• 319 new monographs
• 3,177 revised monographs
• 10 deleted monographs
• 6 consolidated entries

Volume I – Traditional Chinese Medicines (TCM)

• 2,711 monographs
• 117 new
• 452 revised

Volume II – Chemical Drugs

• 2,712 monographs
• 117 new
• 2,387 revised

Volume III – Biological Products

• 153 monographs
• 20 new
• 126 revised

Volume IV – General Technical Requirements

This volume contains 361 general chapters, including:

• 38 general requirements for pharmaceutical preparations (35 revised)
• 281 general testing methods and technical chapters (35 new, 51 revised)
• 42 technical guidelines (12 new, 12 revised)

The English edition also includes 335 pharmaceutical excipient monographs, featuring:

• 65 new monographs
• 212 revised monographs

What Has Changed?

One of the main features of the latest edition of the Pharmacopoeia is its focus on modern technologies and novel drug development approaches. This includes updated guidelines on biologics, traditional Chinese medicines and complementary therapies, making it a more comprehensive and inclusive guide to the latest advancements in the field.

The 2020 Pharmacopoeia is designed to keep pace with the rapid changes in the pharmaceutical industry with a particular focus on innovation and evolution. Whether it is new production processes, the introduction of new drug categories or emerging drug delivery mechanisms, the Pharmacopoeia provides quality measures and guidance to ensure that such developments meet the highest standards of safety and efficacy.

Overall, the English version of the 2020 Pharmacopoeia represents a valuable resource for the pharmaceutical industry and individuals alike. The new release ensures that the latest standards are widely available and accessible across borders, making it easier to ensure the quality and safety of drugs sold and distributed in China from a global perspective. The Pharmacopoeia is an essential tool for ensuring the wellbeing of individuals and society as a whole and remains an important reference document in the ongoing efforts to improve global public health.

Reach out to Cisema if you have interest in any particular topics of the 2020 CP or discover our services for manufacturers of pharmaceuticals, packaging and ingredients.

Further information

Explore Cisema's pharmaceutical services for international companies entering and operating in China, including:

• Pharmaceutical Strategy Consulting
• Pharmaceutical Market Access Consulting
• Pharmaceutical Regulatory Affairs Consulting
• Pharmaceutical Compliance Consulting & Quality Management
• Pharmacovigilance Consulting Services

Refer to our article Chinese Pharmacopoeia 2025: Key Updates and What You Need to Know for the latest standards and updates.